Sarpogrelate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sarpogrelate
Sarpogrelate structure.png
Clinical data
Other namesSarpogrelate, (−)-4-[1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
AHFS/Drugs.comInternational Drug Names
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H31NO6
Molar mass429.506 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Sarpogrelate (brand name Anplag; former developmental code names MCI-9042, LS-187,118) is a drug which acts as an antagonist at the 5HT2A[1][2] and 5-HT2B[3] receptors. It blocks serotonin-induced platelet aggregation, and has applications in the treatment of many diseases including diabetes mellitus,[4][5] Buerger's disease,[6] Raynaud's disease,[7] coronary artery disease,[8] angina pectoris,[9] and atherosclerosis.[10]

See also[edit]

References[edit]

  1. ^ Pertz H, Elz S (April 1995). "In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery". The Journal of Pharmacy and Pharmacology. 47 (4): 310–6. doi:10.1111/j.2042-7158.1995.tb05801.x. PMID 7791029.
  2. ^ Nishio H, Inoue A, Nakata Y. "Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes". Archives Internationales De Pharmacodynamie Et De Therapie. 331 (2): 189–202. PMID 8937629.
  3. ^ Muntasir HA, Hossain M, Bhuiyan MA, Komiyama T, Nakamura T, Ozaki M, Nagatomo T (July 2007). "Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding". Journal of Pharmacological Sciences. 104 (3): 274–7. doi:10.1254/jphs.sc0060241. PMID 17609583.
  4. ^ Pietraszek MH, Takada Y, Taminato A, Yoshimi T, Watanabe I, Takada A (April 1993). "The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus". Thrombosis Research. 70 (2): 131–8. doi:10.1016/0049-3848(93)90154-g. PMID 8322284.
  5. ^ Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, et al. "The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients". Clinical and Experimental Pharmacology & Physiology. 26 (5–6): 461–4. PMID 10386239.
  6. ^ Rydzewski A, Urano T, Hachiya T, Kaneko H, Baba S, Takada Y, Takada A (December 1996). "The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease". Thrombosis Research. 84 (6): 445–52. doi:10.1016/s0049-3848(96)00212-5. PMID 8987165.
  7. ^ Igarashi M, Okuda T, Oh-i T, Koga M (October 2000). "Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist". The Journal of Dermatology. 27 (10): 643–50. doi:10.1111/j.1346-8138.2000.tb02246.x. PMID 11092268.
  8. ^ Satomura K, Takase B, Hamabe A, Ashida K, Hosaka H, Ohsuzu F, Kurita A (January 2002). "Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease". Clinical Cardiology. 25 (1): 28–32. doi:10.1002/clc.4950250108. PMC 6654074. PMID 11808836.
  9. ^ Kinugawa T, Fujita M, Lee JD, Nakajima H, Hanada H, Miyamoto S (August 2002). "Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris". American Heart Journal. 144 (2): E1. doi:10.1067/mhj.2002.124056. PMID 12177659.
  10. ^ Hayashi T, Sumi D, Matsui-Hirai H, Fukatsu A, Arockia Rani PJ, Kano H, et al. (May 2003). "Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism". Atherosclerosis. 168 (1): 23–31. doi:10.1016/s0021-9150(03)00054-6. PMID 12732383.